Organization | Teagasc

Teagasc Report issue

Government Phase 4

Organization Overview

First Clinical Trial

2015

NCT02526004

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Teagasc

Active Ingredients

Drugs in Phase 4 Trials (3)

elexacaftor (Trifakta) (1 trial)

ivacaftor (Kalydeco) (1 trial)

tezacaftor (Trifakta) (1 trial)

Drugs in Other Trials (5)

bacillus subtilis (2 trials)

ceftazidime (fortaz) (1 trial)

Junlebao N1115 (1 trial)

maltodextrin (2 trials)

tobramycin (nebcin) (1 trial)

Indications

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 8